Clinical Experts Meeting on Lymphatic Filariasis

February 22-23, 2016
New Delhi, India

The DNDi Indian office and the Indian Council of Medical Research (ICMR) organized a clinical experts meeting on lymphatic filariasis (LF). The meeting objectives were; to identify the unmet needs for the treatment of LF patients in Asia and; to define the target product profile (TPP) for LF case management in Asia.

 

Concept Note

Agenda

Opening Session

Date: February 22 2016
Time: 09:00-10:30

 

Welcome
Suman Rijal, Director DNDi India office
The DNDi model and DNDi R&D Ooverview
Graeme Bilbe, R&D Director, DNDi
DNDi filariasis programme objectives and meeting agenda
Claudia Pena Rossi, Head, Filarial Program, DNDi
Indian Council of Medical Research (ICMR) activities on filariasis
Rashmi Arora, Head, Division of Epidemiology & Communicable Diseases, ICMR
Opening Remarks
A C Dhariwal, Director, National Vector Borne Disease Control Program
Swarup Kumar Sarkar, Director Communicable Disease, WHO-SEARO
Soumya Swaminathan , Director General, ICMR

 

Session 1

Date: February 22 2016
Time: 10:45-12:30

Burden of LF in 2015 and estimated projections 2020-2025

LF epidemiology and global control program
Ahmed Jamsheed Mohamed, Medical Officer-VBN WHO Regional Office for South-East Asia
LF in India: Current burden and control program progress
P K Srivastava, LF India National Program, NVBDCP
PacELF – Eliminating lymphatic filariasis in the Asia Pacific
Kazuyo Ichimori, Professor, Institute of Tropical Medicine, Nagasaki University.
Projected LF prevalence (infection and morbidity) in 2020-2025
Dr. Wilma Stock, Senior Researcher/Epidemiologist. Erasmus MC University Medical Center Rotterdam
General discussions and conclusions on future burden of LF

 

Session 2

Date: February 22 2016
Time: 13:30-15:15

LF pathogenesis, clinical manifestations and diagnosis in Asia

Pathogenesis of LF
V. Kumaraswami. Former Director of Tuberculosis Research center, Chennai, India.
Diagnosis
Gary Weil. Professor, Washington University School of Medicine
Clinical manifestations and patient categories
Suma TK. Prof of Internal Medicine, Medical College Hospital, Alappuzha, Kerala
General discussions and conclusion on patient subpopulations

 

Session 3

Date: February 22 2016
Time: 15:30-16:00

LF treatment

Efficacy of current treatments on LF morbidity
Suma TK. Prof. of Internal Medicine. Medical College Hospital, Alappuzha, Kerala
Efficacy of current treatments on the parasite (micro and macrofilaricidal effect)
K. Ramaiah Consultant LF

 

Session 3

Date: February 22 2016
Time:
16:00-17:45

New treatments under investigation

Preliminary results of current clinical trials on LF
Gary Weil. Professor Washington University School of Medicine
Doxycycline effect on the LF parasites and on morbidity
Alex Debrah. Parasitology lecturer at Kwame Nkrumah University of Science and Technology (KNUST)
Studies on new treatments on Filariasis in India
Jambulingam, Scientist G & Director – Vector Control Research Centre
 General discussions and conclusion on main efficacy gaps

Session 4

Date: February 23 2016
Time: 09;:00-13:00

TPP for LF case management

Patients perspective
Mitali Mohanty from the LEPRA Society. Project director of the LF programme in Puri district, Odisha.
Presentation of the results of the survey done among physicians treating patients
Thomas John, DNDi consultant
Questions
Introduction TPP (DNDi)
Nathalie Strub-Wourgaft, Medical Director, DNDi
Defining the TPP
Moderator panel 1: A. C. Dhariwal Director, National Vector Borne Disease Control Program (TBC)
Moderator panel 2: Rashmi Arora, Head, Division of Epidemiology & Communicable Diseases, ICMR (TBC)
Conclusion
Suman Rijal, Director, DNDi, India